Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630733 · ClinicalTrials.gov registry record · Phase 3
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 664
- Enrollment target
NCT01630733 is a Phase 3 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 664 participants.
The verdict
NCT01630733, a Phase 3 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 664 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
Interventions
- DRUG Docetaxel
- DRUG Custirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2012-10-24 |
| Est. Completion | 2016-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01630733
The ClinicalTrials.gov registry entry for NCT01630733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01630733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01630733 about?
NCT01630733 is a clinical study titled "A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer". The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
What is the current status of trial NCT01630733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 664 participants. The study started on 2012-10-24. Estimated completion is 2016-11-17.
What interventions are being tested in trial NCT01630733?
The interventions under investigation include: Docetaxel (DRUG), Custirsen (DRUG).
Who is sponsoring clinical trial NCT01630733?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.